Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study-Reference-Cited by-同舟云学术

Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study

Published:2020-12 Issue:12 Volume:42 Page:2321-2330.e0
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Feriozzi Sandro,Linhart Ales^ORCID,Ramaswami Uma,Kalampoki Vasiliki,Gurevich Andrey,Hughes Derralynn

Funder

Shire International GmbH

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference24 articles.

1. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey;Mehta;Eur J Clin Invest,2004

2. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial;Banikazemi;Ann Intern Med,2007

3. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment;Kampmann;Orphanet J Rare Dis,2015

4. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders;Wyatt;Health Technol Assess,2012

5. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa;Hughes;Heart,2008

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term safety of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: post-marketing extension surveillance in Japan;Molecular Genetics and Metabolism Reports;2024-09

2. Clinical outcomes in elderly patients receiving agalsidase alfa treatment in the Fabry Outcome Survey;Molecular Genetics and Metabolism;2024-09

3. Prognostic Implications of Left Ventricular Hypertrophy and Mechanical Function in Fabry Disease: A Longitudinal Cohort Study;Journal of the American Society of Echocardiography;2024-08

4. Plot thickens: the progression of left ventricular ‘hypertrophy’ in Fabry disease;Heart;2024-07-23

5. Updated Evaluation of Agalsidase Alfa Enzyme Replacement Therapy for Patients with Fabry Disease: Insights from Real-World Data;Drug Design, Development and Therapy;2024-04